A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A 0201-positive Patients with Advanced MAGE-A4-positive Cancer
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
Study ID
Protocol Number: 19-2311
More information available at ClinicalTrials.gov: NCT03973333
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers